Cartalax
Cartalax is a Russian-developed synthetic tripeptide bioregulator (reported as Ala-Glu-Asp) marketed for cartilage and joint support, but no peer-reviewed animal or human studies specifically testing Cartalax under that name (or its proposed sequence) were found in PubMed/PMC searches — available support is indirect, drawn from the broader Khavinson short-peptide bioregulator research program.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Cartalax is described as belonging to a class of short synthetic peptides ('peptide bioregulators') that, according to research from the Khavinson group, may act as short peptide-based gene expression regulators capable of entering cell nuclei and interacting with DNA and histone proteins to influence transcription in a tissue-specific manner. This general class-level mechanism has been described for short peptide bioregulators broadly, including in the context of chondrogenic (cartilage) cell differentiation, but it has not been directly demonstrated for Cartalax/the AED sequence itself in any peer-reviewed, PubMed-indexed study identified in this research.
Typical results seen in research
No dedicated animal or human efficacy studies of Cartalax specifically were identified in PubMed or PMC searches. Related publications from the same research group on peptide regulation of gene expression and chondrogenic stem cell differentiation provide indirect, class-level theoretical support, but they do not constitute direct evidence that Cartalax itself improves cartilage health, joint pain, or any clinical outcome — claims of effectiveness for this specific peptide should be treated as unverified.
How it’s commonly used
Where short peptide bioregulators of this general type are used in research, they are typically administered by subcutaneous injection or, in some formulations, taken orally or sublingually over short, defined research cycles; no peer-reviewed, Cartalax-specific administration protocol was identified in the literature reviewed.
- Molecules · 2021 Peptide Regulation of Gene Expression: A Systematic Review
- International Journal of Molecular Sciences · 2023 Peptide Regulation of Chondrogenic Stem Cell Differentiation
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.